30 closest matches · ranked by relevance
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Stage IV Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Percentage of Participants With Reduction in Grade 3/4 Neutropenia — 40; 13 percentage of participants
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Mesothelioma
Primary: Best Response — 0; 7; 11; 11 participants
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Mesothelioma
Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Malignant Pleural Mesothelioma · Non-Small Cell Lung Cancer
Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
Mesothelioma · Adenocarcinoma of Lung · Pancreatic Neoplasms
Primary: Response Assessment — 0; 0; 0; 0 Participants
Malignant Pleural Mesothelioma
Primary: Overall Survival — 17.6; 15.5 Months — p=0.2840
Biphasic Mesothelioma · Epithelioid Mesothelioma · Peritoneal Malignant Mesothelioma
Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants
Malignant Pleural Mesothelioma · Solid Tumors
Primary: 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin — 25; 9; 27; 13…